Buğra ÇOŞKUN, Selçuk ERKİLİNÇ, Özgür KARA, Bora ÇOŞKUN, Burak ELMAS, Dilek ŞAHİN

The Investigation of Prenatal Screening Test Parameters in Predicting HELLP Syndrome

We aimed to investigate whether first and second-trimester prenatal screening test parameters may be useful in predicting HELLP Syndrome. HELLP syndrome was defined according to Sibai criteria. The collected data were as follows; age, gravida, parity, body mass index, gestational week at labor, route of delivery, birth weight, aspartate aminotransferase (AST), Lactate dehydrogenase (LDH), bilirubin, first trimester multiple of medians (MOM) of pregnancy-associated plasma protein-A (PAPP-A) and Beta human chorionic gonadotropin (B hCG), second trimester B hCG, unconjugated estriol (uE3) and AFP levels were measured. A total of 80 patients in the study group and 135 patients in control groups were included in the study. All the markers of HELLP syndrome were significantly higher in the study group due to the markers was the criteria for HELLP syndrome. While first-trimester PAPP-A was significantly lower in the study group, B hCG levels were similar between groups. The second trimester B hCG level was significantly higher in the study group. AFP level and uE3 level were not different in the control and study groups. Low PAPP-A levels and high second trimester B hCG levels may be associated with HELLP syndrome in subsequent gestational weeks.

PDF

___

1. Obstetricians ACo, Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstetrics and gynecology 2013; 122: 1122.

2. Rimaitis K, Grauslyte L, Zavackiene A, Baliuliene V, Nadisauskiene R, Macas A. Diagnosis of HELLP Syndrome: A 10-Year Survey in a Perinatology Centre. International journal of environmental research and public health 2019; 16: 109.

3. Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. European Journal of Obstetrics & Gynecology and Reproductive Biology 2013; 166: 117-123.

4. Shenhav S, Gemer O, Volodarsky M, Zohav E, Segal S. Midtrimester triple test levels in women with severe preeclampsia and HELLP syndrome. Acta obstetricia et gynecologica Scandinavica 2003; 82: 912-915.

5. Oliveira N, Poon LC, Nicolaides KH, Baschat AA. First trimester prediction of HELLP syndrome. Prenatal diagnosis 2016; 36: 29-33.

6. Rink BD, Norton ME, editors. Screening for fetal aneuploidy. Seminars in perinatology; 2016: Elsevier.

7. Zhong Y, Zhu F, Ding Y. Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis. BMC pregnancy and childbirth 2015; 15: 191.

8. Gaccioli F, Aye IL, Sovio U, Charnock-Jones DS, Smith GC. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. American journal of obstetrics and gynecology 2018; 218: 725-737.

9. Smith GC. First-trimester determination of complications of late pregnancy. JAMA. 2010;303(6):561-2.

10. Conover CA, Bale LK, Overgaard MT, et al. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development 2004; 131: 1187-1194.

11. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. The Journal of Clinical Endocrinology & Metabolism 2002; 87: 1762-1767.

12. Bonno M, Oxvig C, Kephart GM, et al. Localization of pregnancy-associated plasma protein-A and colocalization of pregnancyassociated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. Laboratory investigation; a journal of technical methods and pathology 1994; 71: 560- 566.

13. Conde‐Agudelo A, Bird S, Kennedy S, Villar J, Papageorghiou A. First‐and second‐trimester tests to predict stillbirth in unselected pregnant women: a systematic review and meta‐analysis. BJOG: An International Journal of Obstetrics & Gynaecology 2015; 122: 41-55.

14. Poon LC, Kametas NA, Pandeva I, Valencia C, Nicolaides KH. Mean arterial pressure at 11+ 0 to 13+ 6 weeks in the prediction of preeclampsia. Hypertension 2008; 51: 1027-1033.

15. Duric K, Skrablin S, Lesin J, Kalafatic D, Kuvacic I, Suchanek E. Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy. European Journal of Obstetrics & Gynecology and Reproductive Biology 2003; 110: 12-15.

16. Dugoff L. First-and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstetrics & Gynecology 2010; 115: 1052-1061.

17. Savasan ZA, Goncalves LF, Bahado-Singh RO, editors. Second-and third-trimester biochemical and ultrasound markers predictive of ischemic placental disease. Seminars in perinatology; 2014: Elsevier.

18. Yaron Y, Cherry M, Kramer RL, et al. Secondtrimester maternal serum marker screening: maternal serum α-fetoprotein, β-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. American journal of obstetrics and gynecology 1999; 181: 968-974.

19. Nunthapiwat S, Sekararithi R, Wanapirak C, et al. Second Trimester Serum Biomarker Screen for Fetal Aneuploidies as a Predictor of Preterm Delivery: A Population-Based Study. Gynecologic and obstetric investigation 2019: 1-8.

20. Gravett CP, Buckmaster JG, Watson PT, Gravett MG. Elevated second trimester maternal serum β‐HCG concentrations and subsequent adverse pregnancy outcome. American journal of medical genetics 1992; 44: 485-486.